Striant SR: a novel, effective and convenient testosterone therapy for male hypogonadism.
Striant SR (marketed as Striant in the US) is a novel sustained-release mucoadhesive buccal testosterone tablet for the treatment of male hypogonadism. Striant SR restores serum testosterone concentrations to the physiological range within 4 h of application, and steady-state concentrations are achieved within 24 h of twice-daily dosing. In phase III clinical trials, 87-97% of patients using Striant SR achieved 24-h-averaged serum testosterone concentrations within the normal range. In a comparative study, Striant SR was more likely to restore testosterone concentrations to the physiological range than Andropatch. In a small study, Striant SR produced steady-state testosterone concentrations comparable with those achieved with a testosterone gel (50mg testosterone). Striant SR was well tolerated, with a low incidence of adverse events and a low discontinuation rate (3.5%) due to adverse events in phase III studies. Striant SR is an effective, well-tolerated, convenient and discreet treatment for male hypogonadism.